A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition

J Biol Chem. 2005 Nov 18;280(46):38424-37. doi: 10.1074/jbc.M505933200. Epub 2005 Sep 1.

Abstract

To find new principles for inhibiting serine proteases, we screened phage-displayed random peptide repertoires with urokinase-type plasminogen activator (uPA) as the target. The most frequent of the isolated phage clones contained the disulfide bridge-constrained sequence CSWRGLENHRMC, which we designated upain-1. When expressed recombinantly with a protein fusion partner, upain-1 inhibited the enzymatic activity of uPA competitively with a temperature and pH-dependent K(i), which at 25 degrees C and pH 7.4 was approximately 500 nm. At the same conditions, the equilibrium dissociation constant K(D), monitored by displacement of p-aminobenzamidine from the specificity pocket of uPA, was approximately 400 nm. By an inhibitory screen against other serine proteases, including trypsin, upain-1 was found to be highly selective for uPA. The cyclical structure of upain-1 was indispensable for uPA binding. Alanine-scanning mutagenesis identified Arg(4) of upain-1 as the P(1) residue and indicated an extended binding interaction including the specificity pocket and the 37-, 60-, and 97-loops of uPA and the P(1), P(2), P(3)', P(4)', and the P(5)' residues of upain-1. Substitution with alanine of the P(2) residue, Trp(3), converted upain-1 into a distinct, although poor, uPA substrate. Upain-1 represents a new type of uPA inhibitor that achieves selectivity by targeting uPA-specific surface loops. Most likely, the inhibitory activity depends on its cyclical structure and the unusual P(2) residue preventing the scissile bond from assuming a tetrahedral geometry and thus from undergoing hydrolysis. Peptide-derived inhibitors such as upain-1 may provide novel mechanistic information about enzyme-inhibitor interactions and alternative methodologies for designing effective protease inhibitors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 4-Aminobenzoic Acid / chemistry
  • Alanine / chemistry
  • Amino Acid Sequence
  • Binding Sites
  • Binding, Competitive
  • Capsid Proteins
  • Catalysis
  • Cell Line
  • DNA / chemistry
  • DNA-Binding Proteins / chemistry
  • Disulfides / chemistry
  • Dose-Response Relationship, Drug
  • Electrophoresis, Polyacrylamide Gel
  • Enzyme Inhibitors / pharmacology
  • Enzyme-Linked Immunosorbent Assay
  • Factor Xa / chemistry
  • Humans
  • Hydrogen-Ion Concentration
  • Inhibitory Concentration 50
  • Kinetics
  • Models, Chemical
  • Models, Molecular
  • Molecular Sequence Data
  • Mutagenesis, Site-Directed
  • Peptide Hydrolases / chemistry
  • Peptide Library
  • Peptides / chemistry
  • Peptides, Cyclic / chemistry*
  • Peptides, Cyclic / physiology
  • Plasminogen / chemistry
  • Protease Inhibitors / pharmacology
  • Protein Binding
  • Protein C / chemistry
  • Protein Conformation
  • Protein Structure, Tertiary
  • Recombinant Proteins / chemistry
  • Substrate Specificity
  • Temperature
  • Thermodynamics
  • Time Factors
  • Trypsin / chemistry
  • U937 Cells
  • Urokinase-Type Plasminogen Activator / chemistry*
  • Viral Fusion Proteins / chemistry

Substances

  • Capsid Proteins
  • DNA-Binding Proteins
  • Disulfides
  • Enzyme Inhibitors
  • Peptide Library
  • Peptides
  • Peptides, Cyclic
  • Protease Inhibitors
  • Protein C
  • Recombinant Proteins
  • Viral Fusion Proteins
  • upain-1 peptide
  • Plasminogen
  • DNA
  • Peptide Hydrolases
  • Trypsin
  • Factor Xa
  • Urokinase-Type Plasminogen Activator
  • Alanine
  • 4-Aminobenzoic Acid